Navigation Links
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
Date:3/31/2009

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, today announced its financial results for 2008.

DOR's revenues for 2008 were approximately $2.3 million compared to $1.3 million in 2007. The increase was due primarily to progress with DOR's September 2006 NIH grant and the resulting achievement of certain research and development milestones with our subcontractors.

DOR's net loss for 2008 was approximately $3.4 million, or $0.03 per share, compared to $6.2 million, or $0.07 per share, for 2007. This decrease in net loss is primarily attributed to lower research and development costs associated with Food and Drug Administration (FDA) and European regulatory matters as well as a reduction in general and administrative expenses. Research and development expenses for 2008 were approximately $1.6 million, compared with $3.1 million for 2007. General and administrative expenses for 2008 were approximately $1.9 million, compared with $2.9 million for 2007.

"2009 is off to a strong start for DOR," stated Christopher J. Schaber, PhD, President and CEO of DOR. "To start the year off, we announced FDA clearance under its Special Protocol Assessment (SPA) procedure to begin our confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD. This, in part, has enabled us to shore up our balance sheet significantly as a result of our partnership with Sigma-Tau Pharmaceuticals. We now have an experienced partner in the HSC transplant arena, regulatory clarity with regard to the Phase 3 development of orBec(R), and a relatively clean capital structure. We have also begun adding key personnel to execute new clinical trials in GI GVHD and radiation enteritis. We are looking forward to initiating the confirmatory Phase 3 clinical trial and are optimistic that 2009 will be a year of substa
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... sell shares of its Common Stock and Series A ... offerings.  The Series A Convertible Preferred Stock is non-voting ... that conversion will be prohibited if, as a result, ... than 4.99% of the Common Stock then outstanding. As ...
(Date:9/17/2014)... MARIETTA, Ga. , Sept. 17, 2014  MiMedx ... integrated developer, processor and marketer of patent protected ... membrane, announced today the publication of another peer-reviewed clinical ... " A Multi-center Randomized Controlled Clinical Trial ...   Amnion/Chorion Membrane Allografts and Multi-layer Compression Therapy ...
(Date:9/17/2014)... & Rockville, MD (PRWEB) September 17, 2014 ... a Small Business Innovation Research (SBIR) grant to support ... The award will provide ITI with approximately $255,000 over ... nuts, a leading cause of food allergy, affect over ... of anaphylaxis behind peanut allergy. Tree nut exposure is ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... March 25 Accera, Inc., a biotechnology company delivering ... announced that the company will be participating at two ... and CEO, will speak at the 2nd Annual BIO ... at the Sheraton Boston Hotel in Boston, MA. On ...
... 25 Shire plc (LSE: SHP, NASDAQ:, SHPGY ... Report and Accounts in respect of the year ended ... has previously announced unaudited full,year 2008 results, prepared in ... year earnings announcement on February 19,2009. , ...
... JOSEPH, Mich., and RALEIGH, N.C., March 25 ... grade televisions and communications solutions to hospitals, today announced ... part of the health system,s strategy to enhance the ... with Lakeland,s vision of improving the hospital experience by ...
Cached Biology Technology:Accera, Inc. to Present at Upcoming Investor Conferences 2Publication of Shire plc's Annual Report 2008 2Publication of Shire plc's Annual Report 2008 3Publication of Shire plc's Annual Report 2008 4Publication of Shire plc's Annual Report 2008 5Publication of Shire plc's Annual Report 2008 6Publication of Shire plc's Annual Report 2008 7Publication of Shire plc's Annual Report 2008 8Publication of Shire plc's Annual Report 2008 9Publication of Shire plc's Annual Report 2008 10Publication of Shire plc's Annual Report 2008 11Publication of Shire plc's Annual Report 2008 12Publication of Shire plc's Annual Report 2008 13Publication of Shire plc's Annual Report 2008 14Publication of Shire plc's Annual Report 2008 15Publication of Shire plc's Annual Report 2008 16Publication of Shire plc's Annual Report 2008 17Publication of Shire plc's Annual Report 2008 18Publication of Shire plc's Annual Report 2008 19Publication of Shire plc's Annual Report 2008 20Publication of Shire plc's Annual Report 2008 21Publication of Shire plc's Annual Report 2008 22Publication of Shire plc's Annual Report 2008 23Publication of Shire plc's Annual Report 2008 24Publication of Shire plc's Annual Report 2008 25Publication of Shire plc's Annual Report 2008 26Publication of Shire plc's Annual Report 2008 27Publication of Shire plc's Annual Report 2008 28Publication of Shire plc's Annual Report 2008 29Publication of Shire plc's Annual Report 2008 30Publication of Shire plc's Annual Report 2008 31Publication of Shire plc's Annual Report 2008 32Publication of Shire plc's Annual Report 2008 33TeleHealth Services and Lakeland HealthCare Connect to Create Outstanding Patient Experience 2TeleHealth Services and Lakeland HealthCare Connect to Create Outstanding Patient Experience 3
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... that the bacterium that causes dysentery uses a 'sword ... research published today in Science, the team from Imperial ... the bacteria which causes dysentery, is able to invade ... , They found that shigella was able to infect ...
... 99 percent of the genes in the adult body. That's ... of bacteria that normally live on and in us. , ... to researchers at the School of Medicine will help fill ... for isolating, sequencing and analyzing the genomes of "friendly" bacteria ...
... in the journal Blood, Yale scientists identify the molecular triggers ... expand into large populations of malignant lymphocytes. , CTCL is ... blood cells of the immune system. Finding CTCL triggering factors ... Director of the Yale Cancer Center, and professor and chair ...
Cached Biology News:W.M. Keck Foundation funds study of friendly microbes 2W.M. Keck Foundation funds study of friendly microbes 3Source of molecular triggers in cutaneous T cell lymphoma identified 2
HOXC11 Antibody...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: